Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

被引：9

作者：

Nakayama, Yoichi ^{[1
]}

Nagata, Wataru ^{[2
]}

Takeuchi, Yoichi ^{[3
]}

Fukui, Sho ^{[4
]}

Fujita, Yuya ^{[5
]}

Hosokawa, Yohei ^{[6
]}

Ueno, Masanobu ^{[5
]}

Ono, Kumiko ^{[7
]}

Sumitomo, Shuji ^{[8
]}

Tabuchi, Yuya ^{[1
]}

Nakanishi, Yuichiro ^{[9
]}

Saito, Shuntaro ^{[10
]}

Ikeuchi, Hiroko ^{[11
]}

Kawamori, Kazutaka ^{[13
]}

Sofue, Hideaki ^{[9
]}

Doi, Goro ^{[14
]}

Minami, Runa ^{[15
]}

Hirota, Tomoya ^{[16
]}

Minegishi, Kaoru ^{[17
]}

Maeshima, Keisuke ^{[18
]}

Motoyama, Ryo ^{[19
]}

Nakamura, Shohei ^{[19
]}

Suzuki, Shotaro ^{[20
]}

Nishioka, Norihiro ^{[11
,12
]}

Wada, Takuma Tsuzuki ^{[21
]}

Onishi, Akira ^{[22
]}

Nishimura, Kenichi ^{[23
]}

Watanabe, Ryu ^{[24
]}

Yanai, Ryo ^{[13
]}

Kida, Takashi ^{[9
]}

Nishiwaki, Hiroki ^{[12
,25
]}

Yajima, Nobuyuki ^{[13
]}

Kaneko, Yuko ^{[10
]}

Tanaka, Eiichi ^{[19
]}

Kawahito, Yutaka ^{[9
]}

Harigai, Masayoshi ^{[19
]}

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto, Japan

[2] Natl Def Med Coll, Dept Pharmacol, Tokorozawa, Saitama, Japan

[3] Japanese Red Cross Maebashi Hosp, Dept Rheumatol & Nephrol, Maebashi, Japan

[4] Kyorin Univ, Sch Med, Dept Emergency & Gen Med, Tokyo, Japan

[5] Univ Occupat & Environm Hlth, Dept Internal Med 1, Kitakyushu, Japan

[6] Hiroshima Univ Hosp, Dept Clin Immunol & Rheumatol, Hiroshima, Japan

[7] Univ Tokyo, Inst Med Sci, Dept Joint Surg, Res Hosp, Tokyo, Japan

[8] Kobe City Med Ctr Gen Hosp, Dept Rheumatol, Kobe, Japan

[9] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Inflammat & Immunol, Kyoto, Japan

[10] Keio Univ, Sch Med, Dept Internal Med, Div Rheumatol, Keio, Japan

[11] Kyoto Univ, Sch Publ Hlth, Grad Sch Med, Dept Prevent Serv, Kyoto, Japan

[12] Kyoto Univ, Fac Med, Kyoto, Japan

[13] Showa Univ, Div Rheumatol, Dept Med, Sch Med, Shinagawa, Japan

[14] Kyushu Univ, Dept Internal Med, Beppu Hosp, Beppu, Japan

[15] Otokoyama Hosp, Dept Orthopaed Surg & Rheumatol, Kyoto, Japan

[16] Univ Fukui Hosp, Dept Infect & Rheumatol, Fukui, Japan

[17] Yokohama City Univ, Dept Stem Cell & Immune Regulat, Grad Sch Med, Yokohama, Japan

[18] Nishida Hosp, Dept Rheumatol, Saiki, Oita, Japan

[19] Tokyo Womens Med Univ Sch Med, Dept Internal Med, Div Rheumatol, 8-1 Kawada Cho,Shinjuku Ku, Tokyo 1628666, Japan

[20] St Marianna Univ, Dept Internal Med, Div Rheumatol & Allergol, Sch Med, Kawasaki, Japan

[21] Saitama Med Univ, Fac Med, Dept Rheumatol & Appl Immunol, Saitama, Japan

[22] Kyoto Univ, Grad Sch Med, Dept Adv Med Rheumat Dis, Kyoto, Japan

[23] Yokohama City Univ, Dept Pediat, Grad Sch Med, Yokohama, Japan

[24] Osaka Metropolitan Univ, Dept Clin Immunol, Grad Sch Med, Osaka, Japan

[25] Showa Univ, Dept Internal Med, Div Nephrol, Fujigaoka Hosp, Yokohama, Japan

来源：

MODERN RHEUMATOLOGY | 2024年 / 34卷 / 06期

关键词：

Clinical practice guidelines; meta-analysis; ozoralizumab; rheumatoid arthritis; systematic review; INHIBITOR TOFACITINIB CP-690,550; MODIFYING ANTIRHEUMATIC DRUGS; ETANERCEPT REFERENCE PRODUCT; SELECTIVE JAK-1 INHIBITOR; PLACEBO-CONTROLLED TRIAL; INADEQUATE RESPONSE; DOUBLE-BLIND; PHASE-III; PARALLEL-GROUP; FILGOTINIB GLPG0634/GS-6034;

D O I：

10.1093/mr/roae049

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: The aim of this article is to update evidence on the efficacy and safety of disease-modifying antirheumatic drugs (DMARDs) and provide information to the taskforce for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis (RA). Methods: We searched various databases for randomised controlled trials on RA published until June 2022, with no language restriction. For each of the 15 clinical questions, two independent reviewers screened the articles, evaluated the core outcomes, and performed meta-analyses. Results: Subcutaneous injection of methotrexate (MTX) showed similar efficacy to oral MTX in MTX-naive RA patients. Ozoralizumab combined with MTX improved drug efficacy compared to the placebo in RA patients with inadequate response (IR) to conventional synthetic DMARD (sDMARD). Rituximab with and without concomitant csDMARDs showed similar efficacy to other biological DMARDs (bDMARDs) in bDMARD-IR RA patients. Combined Janus kinase inhibitors and MTX achieved similar clinical responses and equal safety during a 4-year period compared to tumour necrosis factor inhibitors in MTX-IR RA patients. Biosimilars showed efficacy equivalent to that of the original bDMARDs in csDMARD-IR and bDMARD-IR RA patients. Conclusions: This systematic review provides latest evidence for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for RA management.

引用

页码：1079 / 1094

页数：16

共 108 条

[11] A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy [J].

Choe, Jung-Yoon ;

Prodanovic, Nenad ;

Niebrzydowski, Jaroslaw ;

Staykov, Ivan ;

Dokoupilova, Eva ;

Baranauskaite, Asta ;

Yatsyshyn, Roman ;

Mekic, Mevludin ;

Porawska, Wieskawa ;

Ciferska, Hana ;

Jedrychowicz-Rosiak, Krystyna ;

Zielinska, Agnieszka ;

Choi, Jasmine ;

Rho, Young Hee ;

Smolen, Josef S. .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :58-64

[12] Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study [J].

Cohen, Stanley ;

Genovese, Mark C. ;

Choy, Ernest ;

Perez-Ruiz, Fernando ;

Matsumoto, Alan ;

Pavelka, Karel ;

Pablos, Jose L. ;

Rizzo, Warren ;

Hrycaj, Pawel ;

Zhang, Nan ;

Shergy, William ;

Kaur, Primal .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (10) :1679-1687

[13] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[14] Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext) [J].

Cohen, Stanley B. ;

Czeloth, Niklas ;

Lee, Eric ;

Klimiuk, Piotr A. ;

Peter, Nuala ;

Jayadeva, Girish .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) :1097-1105

[15] A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy [J].

Cohen, Stanley B. ;

Alten, Rieke ;

Kameda, Hideto ;

Hala, Tomas ;

Radominski, Sebastiao C. ;

Rehman, Muhammad I. ;

Palaparthy, Ramesh ;

Schumacher, Karl ;

Schmitt, Susanne ;

Hua, Steven Y. ;

Ianos, Claudia ;

Sewell, K. Lea .

ARTHRITIS RESEARCH & THERAPY, 2018, 20

[16] Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis [J].

Cohen, Stanley B. ;

Burgos-Vargas, Ruben ;

Emery, Paul ;

Jin, Bo ;

Cronenberger, Carol ;

Vazquez-Abad, Maria-Dolores .

ARTHRITIS CARE & RESEARCH, 2018, 70 (11) :1598-1606

[17] Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial [J].

Combe, Bernard ;

Kivitz, Alan ;

Tanaka, Yoshiya ;

van der Heijde, Desiree ;

Simon, J. Abraham ;

Baraf, Herbert S. B. ;

Kumar, Uma ;

Matzkies, Franziska ;

Bartok, Beatrix ;

Ye, Lei ;

Guo, Ying ;

Tasset, Chantal ;

Sundy, John S. ;

Jahreis, Angelika ;

Genovese, Mark C. ;

Mozaffarian, Neelufar ;

Landewe, Robert B. M. ;

Bae, Sang-Cheol ;

Keystone, Edward C. ;

Nash, Peter .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07) :848-858

[18] The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study [J].

Cross, Marita ;

Smith, Emma ;

Hoy, Damian ;

Carmona, Loreto ;

Wolfe, Frederick ;

Vos, Theo ;

Williams, Benjamin ;

Gabriel, Sherine ;

Lassere, Marissa ;

Johns, Nicole ;

Buchbinder, Rachelle ;

Woolf, Anthony ;

March, Lyn .

ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (07) :1316-1322

[19] Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial [J].

Curtis, Jeffrey R. ;

Yamaoka, Kunihiro ;

Chen, Yi-Hsing ;

Bhatt, Deepak L. ;

Gunay, Levent M. ;

Sugiyama, Naonobu ;

Connell, Carol A. ;

Wang, Cunshan ;

Wu, Joseph ;

Menon, Sujatha ;

Vranic, Ivana ;

Gomez-Reino, Juan J. .

ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 (03) :331-343

[20] Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis [J].

Edwards, Christopher J. ;

Monnet, Joelle ;

Ullmann, Martin ;

Vlachos, Pantelis ;

Chyrok, Veranika ;

Ghori, Vishal .

CLINICAL RHEUMATOLOGY, 2019, 38 (12) :3381-3390

← 1 2 3 4 5 6 7 8 9 10 →